ArticleDiabetes, obesity & metabolism2025
Treat to target in weight management with semaglutide: Real-world evidence from an eHealth clinic.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.Diabetes, obesity & metabolism · 2026Trial
- Adaptive maintenance after incretin-induced weight loss: Moving beyond the continue-or-stop paradigm.Obesity pillars · 2026Article
- Early Weight Regain After GLP-1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De-Escalation Strategies.Diabetes, obesity & metabolism · 2026Review
- A survey of primary care physicians' views on supporting patients who lose insurance coverage for Glucagon-Like Peptide-1-based drugs for weight management.Obesity pillars · 2026Article
- The evolving landscape of obesity pharmacotherapy.Nature reviews. Drug discovery · 2026Review
- Weight maintenance after discontinuation of GLP-1 therapies.EClinicalMedicine · 2026Review
- Pre-Treatment Concerns and Their Association With Functioning and Well-Being During Incretin-Based Therapy: A Cross-Sectional Study.Diabetes, obesity & metabolism · 2026Article
- Optimizing Obesity Management With GLP-1 Agonist Medication Through Mobile Health Technology, Nutrition Therapy, and Progressive Strength Training: A Retrospective Program Review.Obesity science & practice · 2026Article
- The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression.EClinicalMedicine · 2026Article
- Real-world semaglutide in obesity cohort: effectiveness, safety and persistence across sex, BMI, and prior GLP-1RA treatment.Frontiers in endocrinology · 2026Article
- Treat to target in weight management with semaglutide: Real-world evidence from an eHealth clinic.Diabetes, obesity & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsTo evaluate the effectiveness of an online multidisciplinary weight loss service combining individualised semaglutide dosing with intensive behavioural therapy (IBT) in adults living with overweight or obesity. MATERIALS AND
methodsThis retrospective cohort study included data from Danish participants enrolled in a digital weight loss programme via the Embla app between January 2022 and September 2024. The programme offered semaglutide with personalised dosing alongside evidence-based recommendations on nutrition, exercise and habits, delivered through IBT. All data collection and monitoring was conducted via the Embla app. The primary outcome was percentage change in body weight at week 64. Secondary outcomes included semaglutide dose, proportions achieving ≥5%, ≥10%, ≥15%, or ≥20% weight loss, and weight change by baseline BMI and dose.
resultsThe study included 2694 participants (78% women, mean age 46.8 ± 10.8 years, mean BMI 34.3 ± 4.8). At weeks 26, 52, and 64, the number of participants that remained in the study was: 1580, 712, and 465. Mean weight loss at week 64 was 16.7% (95% CI: -17.4 to -16.0) with a mean semaglutide dose of 1.08 mg/week (SD 0.54). A total of 98% achieved ≥5% and 82% achieved ≥10% weight loss. Weight change was consistent across BMI classes and medication doses.
conclusionsParticipants achieved clinically meaningful weight loss comparable to that seen in randomised trials, despite using lower semaglutide doses. These findings support the effectiveness of a personalised, treat-to-target approach integrating medical and behavioural obesity management in a digital setting.
trial registrationhttps://osf.io/86kmc/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.